TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00122421

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist recommendations to primary care providers
Description: recommendations based on chart review by pharmacist, given to pcp at time of visit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacist recommendations
Description: recommendations based on chart review by pharmacist, given to pcp at time of visit
Study: NCT01730287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control
Description: The teeth in this group restored only by filling material,without liner application.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide
Description: Calcium Hydroxide paste applied.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate(MTA)
Description: MTA applied .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEM cement
Description: CEM cement applied .
Study: NCT00502580

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview taking about 10 minutes to complete.
Study: NCT04685213

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Stimulation
Description: Subjects will receive an active electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electrical Stimulation - Sham
Description: Subjects will receive a sham electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
Study: NCT02932826

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Regulatory T cells Therapy
Description: Receive Treg infusion: 1\~5\*10\^6/kg b.w. in 100ml NS
Study: NCT00304031

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent radiation therapy
Description: 60 Gy in 2 Gy fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent radiation therapy
Description: 60 Gy in 2 Gy fractions
Study: NCT02932826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Treated according to routine clinical practice at the discretion of the treating physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Treated according to routine clinical practice at the discretion of the treating physician
Study: NCT02015039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BoNT Injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BoNT Injections

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Study: NCT01296503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide plus dexamethasone
Description: D+60 after ASCT: randomization in two arms of maintenance: Arm A (dexamethasone alone 40 mg/day for 4 days every 28 days) and Arm B (dexamethasone plus thalidomide 200 mg by mouth daily) for 12 months or until disease progression.~The dose of thalidomide could be reduced if the patient experienced grade 2 or higher adverse events. In this case, thalidomide was discontinued and re-challenged at a lower dose after resolution of the adverse event.
Study: NCT00304031

Intervention type: RADIATION
Group type: OTHER
Intervention: Concurrent radiation therapy
Description: 60 Gy in 2 Gy fractions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle
Description: Oral temozolomide on days 1-5 of a 28-day cycle. Dose starts at 150mg/m2 for first cycle, increases to 200mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
Description: Oral temozolomide on days 1-21 of a 28-day cycle. Dose starts at 75mg/m2 for first cycle, increases to 100mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.
Study: NCT02872480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACTIVE Training
Description: Participants will be asked to complete aerobic exercise on a stationary bike during 30-minute sessions. Intensity will progress under a standard procedure for healthy participants (60-80% of VO2max) and as tolerated by concussed participants (starting at 60% of symptom exacerbation).
Study: NCT01296503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone alone 40 mg/day for 4 days every 28 days
Study: NCT04201639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verofilcon A contact lenses
Description: Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
Study: NCT03018860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Moderate management
Description: After randomization, women allocated to the intervention group, i.e. moderate pushing, are encouraged to push only 2 times per contractions, to respect contractions without pushing and there is no limit of pushing duration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intensive management
Description: This group corresponds to usual obstetrical management of active second stage in France. In France, national guidelines recommend to limit maternal expulsive efforts to 30 minutes (grade C). Thus, physicians (midwives and obstetricians) encourage usually women to push 3 times per contractions and to push on every contraction in order to deliver into a 30 minutes timing.
Study: NCT02965989

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Online training of a nursing technique
Description: The professionals with participant in the experimental arm receive an online training of a technique of extraction of blood culture and other arm the professionals no receive any training. They work as usual.
Study: NCT01745653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham procedure
Study: NCT01718158

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon Lambda-1a

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Study: NCT00967681

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oncoxin
Description: (caplets 300 mg), three oral caplets per day for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (caplets 300 mg), three oral caplets per day for 24 weeks
Study: NCT01823081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection of bevacizumab (Avastin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection of fasudil and bevacizumab (Avastin)
Description: intravitreal injections of bevacizumab and fasudil are performed at two different sites (superior temporal and inferior temporal quadrants respectively)
Study: NCT02082964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCIM
Description: after lecture students had rotation in 6 groups through 6 stations, trained and practiced under supervision of 6 instructors about Initial Steps, Positive Pressure Ventilation(PPV), Intubation, Chest Compressions, Medications and management of advanced resuscitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video
Description: video about neonatal resuscitation presented then students repeated the video. Workshops was based on NRP and lasted 6 hours for each group the contentof the video was based on the educational content of the course
Study: NCT00542126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decapeptyl 0.1 mg after embryo transfer
Description: Decapeptyl 0.1 mg (Ferring, Kiel, Germany) 3 days following embryo transfer
Study: NCT02311881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg SR tablets
Description: Two paracetamol 1000 mg SR tablets administered orally two times a day plus two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol 665 mg SR tablets
Description: Two paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
Study: NCT04262479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel
Description: 3 intra-inguinal injections (into the lymph nodes) of GAD-alum one month apart. Supplier Diamyd Medical AB in Stockholm, Sweden

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 1 tablet/day, total daily dose of 2000 IE given per os from day -30 through day 90. Supplier Meda, Solna, Sweden
Study: NCT05052944

Intervention type: DEVICE
Intervention: Cochlear implantation
Description: Patients who receive cochlear implant for single-sided deafness
Study: NCT02225652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC (Fluorouracil, Epirubicin, Cyclophosphamide) + filgrastim + paclitaxel
Study: NCT01469481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532
Description: a single oral dose of \[14C\]PF-04991532 (450 mg/100 uCi suspension)
Study: NCT03739151

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral Obesity Treatment
Description: Self-monitoring. Participants will be taught to record their weight, the calories of each food item, and physical activity using a method of their choice (e.g., commercial smartphone app, paper diary). The clinician will review dietary intake and provide personalized feedback at the outset of session.~Diet. Per national guidelines for weight loss, a daily goal of 1200-1800 kcal/day will be prescribed depending on baseline weight. A Mediterranean diet will be prescribed to meet the recommended calorie goal and be consistent with dietary recommendations for CVD patients.~Exercise. Participants will be encouraged to achieve 250 minutes/week of moderate intensity activity in accordance with current national recommendations for physical activity among individuals attempting weight loss. Participants will be encouraged to gradually increase activity level to achieve approximately 50 minutes of activity over five days per week.
Study: NCT03226847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Vein Isolation
Description: Standard antral pulmonary vein isolation using radiofrequency ablation catheters
Study: NCT00249587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: dosed to effect, every six hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: dosed to effect, every six hours
Study: NCT03666338

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early, goal-directed mobilization
Description: Early, goal directed mobilization using (1) the SOMS algorithm and (2) facilitator
Study: NCT00739531

Intervention type: DEVICE
Intervention: Exhaled nitric oxide (eNO)
Description: Subjects will perform a controlled breath maneuver using both the Apieron and NIOX devices. The devices will measure nitric oxide in the subjects' exhaled breath.
Study: NCT04965415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Links + Leadership Training
Description: Help businesses undergo transactional (i.e., business management practices) and transformational (i.e., business leadership and culture) change. Transactional change component: Health Links is an existing community-based intervention that seeks to help businesses - especially small and medium-sized businesses - incorporate Total Worker Health (TWH) programming into their business practices through assessment, advising, and certification. There is evidence that this consultation intervention is effective at helping businesses develop and implement policies and programs.Transformational change component: The experimental arm includes TWH leadership training for small business owners and other senior leaders. This is a three-month training that includes assessments, in-person training, and virtual training transfer activities. The goal is to help the leader understand their organization's current approach to TWH, identify areas for improvement, and to take action.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Links
Description: Health Links is an existing community-based intervention that seeks to help businesses - especially small and medium-sized businesses - create a culture of both safety and health. Health Links does this by helping businesses incorporate Total Worker Health (TWH) programming into their business practices through assessment, advising, and certification. There is evidence that this consultation intervention is effective at helping businesses develop and implement policies and programs.
Study: NCT05101941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate dental implants
Description: Implants will be immediately placed in sockets associated with chronic periapical granuloma Extraction of non-restorable Teeth with periapical granuloma and socket debridement will be done then implants will be placed
Study: NCT02134951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: intravenous infusion of saline solution with ketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be used for placebo in this group
Study: NCT02555475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: community based hepatitis C care and treatment
Study: NCT01536834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device
Study: NCT01535690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: photodynamic therapy and periodontal debridement
Description: At least two teeth (one with PD ≥ 7 mm and another with PS ≥ 5 mm) were randomly assigned (by coin toss) to one of the treatments: with (test group) or without PDT (control group). After random allocation, all patients received full-mouth ultrasonic debridement using an ultrasonic scaler for 1 hour. Specific tips were used. PDT was performed on only one side of the mouth and the initial step was subgingival irrigation with 0.005% methylene blue dye. To avoid contamination of the control sites with the dye, the methylene blue was applied only inside the periodontal pockets and a high-powered suction device controlled the flow. Two minutes after applying the photosensitizer, the low power laser - AsGaAl was applied for 90 seconds.
Study: NCT00434304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole prolonged release/extended release(PR/XR)
Description: Subjects will take the investigational drug once daily at the same time each day, it is recommended that this is in the morning for optimal benefit. Investigational drug is taken for 52 weeks, starting on the next day of the Week 0 visit. One tablet of ropinirole PR/XR 2 mg tablets will be orally dosed as the initial dose. The dose will be titrated weekly by 2 mg/day, and increased to 8 mg/day in Week 4. From Week 5 up to 16, the dose will be increased at minimum intervals of one week between titration steps until sufficient efficacy is obtained, according to individual clinical response and tolerability (the dose may be titrated up to 16 mg/day). In Week 16 and further, treatment dose at Week 16 will be continuously administered up to Week 52. If insufficient efficacy is judged in a subject during treatment, or unable to maintain the dose due to adverse event, the treatment dose may be changed. The dose is down tapered according to the maintenance dose at Week 52 (or withdrawal).
Study: NCT01101594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hLL1-DOX (the doxorubicin conjugate of milatuzumab)
Description: hLL1-DOX will be administered intravenously (through a vein) on days 1, 4, 8 \& 11 every 21 days for up to 8 treatment cycles. 4 different dose levels of hLL1-DOX will be studied for safety and tolerability.
Study: NCT04418973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VOCs analysis in exhaled air
Description: using an electronic nose and a mass spectrometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VOCs analysis in exhaled air
Description: using an electronic nose and a mass spectrometry
Study: NCT02356341

Intervention type: DEVICE
Intervention: NovaTears® Eye Drops
Description: Topical eye drops for lubrication of the ocular surface
Study: NCT03804580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osimertinib
Description: Non-randomized trial, all patients receive therapy
Study: NCT01582100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reletex
Description: Neuromodulation device worn on the wrist
Study: NCT02106182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Study: NCT01747811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wavelength-1 bright light
Description: 6 weeks of daily light exposure, 30 minutes per morning
Study: NCT02779868

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: patients included in this group will take 2g (4 capsules) per day of eicosapentaenoic acid.
Study: NCT01747811

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: wavelength-2 bright light
Description: 6 weeks of daily light exposure, 30 minutes per morning
Study: NCT04255277

Intervention type: DRUG
Group type: OTHER
Intervention: Combined oral contraceptives (COC)
Description: A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COC)
Description: A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COC)
Description: A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.

Intervention type: DRUG
Group type: OTHER
Intervention: Combined oral contraceptives (COC)
Description: A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.

Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin 400mg
Description: A commercially available formulation of moxifloxacin 400 mg will be used and administered open-label. All tablets will be from the same batch.

Intervention type: DRUG
Group type: OTHER
Intervention: Cenerimod 0.5 mg
Description: This will be administered orally as a film-coated tablet in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod 0.5 mg
Description: This will be administered orally as a film-coated tablet in the morning.
Study: NCT02779868

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: patients included in this group will take 4 capsules per day of olive oil.
Study: NCT01059357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Da Vinci Robotic Transoral Robotic Surgical System
Description: (TORS) Da Vinci Robotic Transoral Robotic Surgical System
Study: NCT01308840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Day 1 and 15 = 6 mg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Days 1 and 15 = 85mg/m2 IV
Study: NCT02077920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride injection
Description: SFDA Approval No. H20045252; Shenyang Zhiying Pharmaceutical Co., Ltd., Liaoning, China
Study: NCT01308840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Days 1 and 15 = 1000 mg/m2 IV
Study: NCT01082081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Description: Paracetamol 1000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg
Description: Paracetamol 500 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02175277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: The first dose of darbepoetin alfa was the same as that administered at the last dosing visit of the active treatment period in Study 20090160. Doses could be increased up to a maximum of 500 μg every two weeks (Q2W).
Study: NCT01980199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole
Description: 600 mg tablets given orally, after the main daily meal~* at the daily dose of 1800 mg (3 tablets) once a day for 4 days~* continued by 1200mg (2 tablets)once a day for 6 days
Study: NCT04212130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BCA method for assessing environmental cleanliness
Description: Evaluating the effectiveness and usability of BCA method which is a new approach in evaluating the effectiveness of environmental cleanliness in intensive care units.~In this study, fluorecan labeling, microbiological sampling and BCA methods will be compared in order to evaluate the effectiveness and usability of BCA method
Study: NCT02477917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac depot with Parietaria judaica pollen extract
Description: Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections